Losartan Potassium prices across Asia continued to decline in early August 2025, following a sharp drop in July driven by high inventory levels, subdued demand, and aggressive stock clearance amid monsoon disruptions. Despite stable raw material inflows and strong manufacturing output, demand remained weak across domestic and export markets. Prices are expected to fall further in late August as oversupply and sluggish procurement persist, limiting any recovery.
Losartan Potassium prices in leading Asian markets continued their downward trend in the first half of August 2025 after strong falls in July. The continuing decline in prices has been mainly because of high stocks and low demand by both domestic and foreign buyers. Although operations in the supply chain are stable and inflows of raw materials are consistent, the market is struggling with oversupply and cautious procurement behavior.
In China, the price of Losartan Potassium decreased substantially in July, due to a confluence of factors. After stalled plants in June, production actions returned to the market with ramped up supply. Adverse weather conditions as flooding in the region and poor monsoons forced the suppliers to increase their pace of stock clearance, subjecting them to cut throat discounting to stay afloat. The manufacturing sector, on the other hand, shrank for the second time in three months, with new export orders declining at a higher pace reflecting global trade uncertainty. Although the Made in China 2025 strategy still encourages mid-to-long-term industrial upgrading, it has not helped the pharmaceutical industry in the short run. Increased input costs were counteracted by heightened competition in the global market which pushed selling prices downwards. The Losartan Potassium supply continued to be healthy, with stable currency exchange rates and seamless logistics, although demand lagged behind.
Demand for Losartan Potassium in China saw a mild decline in July, with reduced offtake from pharmaceutical and healthcare sectors. Export demand softened as overseas buyers, particularly in North America and Europe, relied on existing inventories and adopted a wait-and-see approach. This cautious stance led to a slowdown in procurement activity for Losartan Potassium, further dampening price recovery. Domestic consumption of Losartan Potassium remained relatively stable, but the marginal weakening in international orders exerted gentle downward pressure on the overall market.
Similar to China, Losartan Potassium prices decreased significantly in India in July. Lower production costs related to lower Chinese API prices allowed Indian manufacturers to maximize production capabilities, which resulted in higher inventories. Government subsidy programs and increased funding also contributed to increasing production. However, severe flooding and the forthcoming monsoon season persuaded suppliers to discount inventory to clear excess stock, further adding downward pressure to Losartan Potassium prices in the open marketplace. Global demand weakened due to uncertainty in trade and increased expectations of higher tariffs initiated by the U.S. further added to a bearish mindset.
The demand for Losartan Potassium in India significantly weakened in July due to reduced offtake from pharmaceutical, cosmetic, and personal care consumer products. Buyers focused on immediate inventory needs and avoided bulk buying plans due to tariff concerns and uncertainty surrounding global trade. Higher stock inventories at suppliers' facilities also discouraged re-stocking of Losartan Potassium in India, creating and enhancing already soft market conditions.
As the second half of August approaches to end, Losartan Potassium prices in Asia are anticipated to remain under downward pressure. Demand has remained sluggish since July's rapid drop and is keeping sentiment weak in the market. High manufacturing throughput is expected to continue bolstering supply levels and limit any possible uptick in prices. Likewise, moderate inflows of raw materials should keep any cost-led upward pressure in check, sustaining a bearish tendency for Losartan Potassium in the region.
With no clear signs of demand recovery, and elevated inventories still in place, the Asian Losartan Potassium market appears to be in for further softness in the coming weeks.
